Tourmaline Bio Highlights Cardiovascular Inflammation Focus And Announces Key Clinical And Strategic Updates At Investor Day; Phase 2 TRANQUILITY Trial Surpasses Enrollment Target, With 143 Total Patients Enrolled
Tourmaline Bio Highlights Cardiovascular Inflammation Focus And Announces Key Clinical And Strategic Updates At Investor Day; Phase 2 TRANQUILITY Trial Surpasses Enrollment Target, With 143 Total Patients Enrolled
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today is hosting its Investor Day, beginning at 10 a.m. ET, during which it will outline progress across its pipeline and provide updates on its strategic priorities.– Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 –
– 第二阶段TRanquility试验超过了招募目标，共招募了143名患者；预计在2025年第二季度发布初步数据 –
– Deepak L. Bhatt, MD, MPH, MBA and Dipender Gill, MD, PhD join Cardiovascular Scientific Advisory Board –
– Deepak L. Bhatt博士、公共卫生硕士、工商管理硕士和Dipender Gill博士、哲学博士加入心血管科学顾问委员会 –
– Company nominates abdominal aortic aneurysm as second cardiovascular indication for pacibekitug, expanding development for inflammation-driven cardiovascular disease –
– 公司提名腹主动脉瘤作为pacibekitug的第二个心血管适应症，扩展针对炎症驱动的心血管疾病的发展 –
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today is hosting its Investor Day, beginning at 10 a.m. ET, during which it will outline progress across its pipeline and provide updates on its strategic priorities.
纽约，2024年12月10日（GLOBE NEWSWIRE）-- Tourmaline Bio, Inc.（Tourmaline）（纳斯达克：TRML）是一家临床后期生物技术公司，正在开发变革性药物，以显著改善生活的影响患者的免疫和炎症疾病的患者的生活，今天将举行投资者日活动，活动于东部时间上午10点开始，期间将概述其管道的进展并提供其战略优先事项的更新。
